Immunosuppressive therapy together with hematopoietic stem cell transplantation is used in the management of acquired severe aplastic anemia. However, despite significant improvement in these two treatment modalities, graft failure and graft-versus-host disease still remains the major challenge that needs to be addressed. 1 Mesenchymal stem cells (MSCs) are adult multipotent cells capable of multipotential differentiation that possess immunosuppressive properties and are in use in the clinical setting to treat graft-versus-host disease. 2, 3 Because of their fundamental function in maintaining HSC self-renewal and regulating hematopoiesis, MSC have also been used to facilitate donor HSC engraftment. 4 In this study we report our experience with a severe aplastic anemia patient who failed to respond to three allogeneic hematopoietic stem cell transplantation, but after the co-administration of MSC fully recovered a hematopoietic system within 4 weeks Letters to the Editor and became transfusion independent. To investigate the role of MSC during the transplant and establish their fate after the hematopoietic recovery, we characterized the MSC isolated from the patient before (pre-transplant) and after (post transplant) his successful transplant and compared them with the normal MSC.
A 26-year-old man was diagnosed with a severe aplastic anemia and was treated with anti-lymphocyte serum with a transient response and then with two cycles of anti-thymoglobulin with no effect. He was then referred for allogeneic hematopoietic stem cell transplantation. The details of the transplantation procedures are given in Table 1 . In the first attempt, after reduced intensity conditioning with cyclophosphamide followed by anti-thymoglobulin, no recovery of hematopoiesis was observed. Two other allogeneic stem cell transplantations were then performed with different conditioning regimens: reduced intensity conditioning together with total body irradiation and myelo-ablative regimen, respectively, but no effect on hematopoiesis was observed and both resulted in graft failure. After treatment with Fludarabine, anti-thymoglobulin and total lymphocyte irradiation, the patient underwent a fourth transplant together with 1 Â 10 6 /Kg MSC isolated from a thirdparty donor. This last attempt was successful and resulted in hematopoietic engraftment and sustained remission. The hematopoietic reconstitution is illustrated in Figure 1a . After a rise in neutrophil count, the patient was injected with a second boost of 1 Â 10 6 cells/Kg MSC from the same MSC donor 26 days later. This resulted in full recovery of his hematopoietic system; before the fourth successful transplant the bone marrow (BM) histology showed no residual hematopoietic tissue, whereas 25 days after transplant normal hematopoietic structures were observed (Figure 1b ).
MSC were isolated from the patient's (recipient) BM samples collected pre-and post-fourth transplant and characterized Table 1 Description of transplant procedures and outcome of the patient Letters to the Editor morphologically and phenotypically. Unlike donor MSC, both pre-and post-transplant recipient MSC of the patient were smaller in size, morphologically heterogeneous, comprising round and flattened cells, as well as spindle-shaped cells.
It is interesting that only lower level of CD105 and absence of CD90, CD106 and CD166 in both pre-and post-transplant MSC from the patient distinguished them from normal donor MSC. 
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Pre-and post-transplant recipient samples and donor DNA samples were then typed by short tandem repeats, and informative loci were screened for quantification of the donor cell percentage in mixed chimerism. The post-transplant BM sample showed full donor engraftment without any residual host DNA or MSC donor DNA being detected. In the post-transplant recipient MSC, we predominantly found host DNA with a small amount of BM donor DNA, but no evidence of donor MSC DNA (Figure 2a) .
In cell proliferation (3-(4,5 dimethylthiazol-2yl) 2,5-diphenyl) tetrazolium bromide (MTT) assay, the pre-and post-transplant recipient MSC showed a significantly higher proliferation rate (Figure 2b , P ¼ 0.00001) compared with donor MSC. When we tested the differentiation ability of these cells a drastic difference in osteogenic differentiation was observed between donor and patient recipient MSC. Indeed, although 80-90% of alkaline phosphatase positive (ALP þ ) osteogenic cells were observed in donor MSC, no ALP þ were observed in recipient pretransplant. Post-transplantation recipient MSCs have reacquired some osteogenic differentiation potential (Figure 2c ). When assessed for the ability of the donor and patient MSC to inhibit T-cell proliferation in response to polyclonal stimuli in vitro, donor MSC inhibited T-cell proliferation in a dose-dependent fashion ( n Po0.05). However, patient MSCs resulted in an antiproliferative effect (40% compared with 65% for control) only at the lowest ratio (1:5) between MSC and target cells (data not shown).
Finally, we tested the in vivo functionality of pre-and posttransplant recipient MSC with a view of determining whether MSC from the patient had a failure in hematopoietic supportive capacity and transplantation had modified this in an in vivo non obese diabetic severe combined immuno deficiency (NOD/SCID) xenotransplant assay. At 8 weeks after an injection a significant increase in human engraftment of cord blood lineage depleted cells was observed when normal MSC were co-injected (Po0.05), as well as with the pre-transplant recipient MSC. On the contrary, post-transplant recipient MSC did not have any significant effect (Figure 3a) . At 12 weeks, an increase in the global engraftment level was observed, but no difference was seen in the presence or absence of MSC (Figure 3b ). MSC could be re-isolated from the BM of mice collected at 8 weeks, but not 12 weeks post transplantation.
These ex vivo isolated and expanded MSC from injected mice were exclusively of human origin, confirming homing of the cells to the BM. In this study, the co-transplantation of MSC resulted in increased neutrophil count and donor chimerism in the patient even after three failed allo-transplantations. The positive role of donor MSC in the engraftment and chimerism has been reported in other cases. 5, 6 This is observed in this study by the BM histology and increased neutrophil count after the fourth transplant. As suggested, donor MSCs do not persist for long-term. 7 Donor MSCs disappeared from the recipient after hematopoietic recovery in the patient and also in our animal experiments 12 weeks after transplantation, suggesting the effect of MSC on engraftment to be only transient. Our data demonstrate that MSC co-injection might help in the initial establishment of HSC in the niche, but after recovery of donor hematopoiesis, donor MSCs might be cleared possibly by the immune system. This transient effect might as well be explained by the disappearance of MSCs seen after 8 weeks in the NOD/SCID mice and justify the lack of donor MSCs engraftment in the patient. An interesting observation was the lack of expression of CD90 in both pre-and post-transplant MSCs and their lack of immuno-suppressive property, which correlates with the finding by Campioni et al.
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Our data show a striking difference in osteogenic potential between pre-and post-transplant recipient MSC, in which the post-transplant MSC recovered from the initial defect and differentiated into osteogenic cells. We speculate that the donor MSCs modified the recipient BM microenvironment, by either a paracrine effect or direct cell-cell-mediated reparative function, allowing recipient MSC to support hematopoietic engraftment. This alteration seems to be essential for the success of HSC engraftment based on the crucial role of osteoblastic cells in the regulation of HSC reported recently. 8 More subjects have to be analyzed to dissect the exact mechanisms by which donor MSC alters the recipient BM microenvironment for successful transplantation.
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